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Dupilumab is an IgG4 antibody directed toward IL-4 and IL-13, two major effectors of the Th2 immunity 
response. It was originally developed for severe and/or refractory atopic dermatitis, nevertheless its use has 
secondarily been broadened to severe asthma 1. 
We report herein the case a 28-year-old, non-smoker male who presented to the emergency department with 
confusion, headaches, emesis and photophobia. His medical history included only a severe atopic dermatitis 
leading to dupilumab initation 4 months earlier. Physical examination revealed a meningoencephalitis 
syndrome, and a bilateral parotidomegaly. Biology exhibited a T4 cells lymphopenia (262/mm3, N=530-1300), 
with a polyclonal hypergammaglobulinemia up to 14.3g/L (N=8-13.5) and an elevated plasmatic Angiotensin 
Converting Enzyme (ACE) (93UI/L, N<70). Cranial MRI revealed a diffuse micronodular meningitis with 
brain infiltration. Cerebrospinal fluid analysis showed an hyperproteinorachia (3,49g/L), an hypercellularity up 
to 80 cells/mm3 with 89 % of lymphocytes, and an ACE elevation up to 1.09 UI/l (N=0.06-0.25). Chest CT-
scan revealed a perilymphatic micronodular lung infiltration, without mediastinal lymphadenopathy. Broncho-
alveolar lavage (BAL) fluid analysis showed an elevated T4/T8 ratio (12.29). Bronchial and accessory salivary 
glands samples examination revealed non-necrotising epithelioid granulomas. Dupilumab was stopped, and a 
corticosteroid treatment was implemented, associated with methotrexate. Under this regimen, the evolution 
was favourable and, to date the patient remains in complete clinical remission, 6 months after systemic sarcoid-
like granulomatosis diagnosis and dupilumab cessation. 
This is the first case of systemic sarcoid-like granulomatosis occurring under dupilumab reported so far 2,3. The 
chronology of disease onset (4 months after treatment initiation), the rarity of the disease, and its particularly 
aggressive form in the present case, raise the question of the role of dupilumab in the disease development. 
The development of non-caseating gigantic granulomas is a hallmark of sarcoidosis. These granulomas are the 
result of macrophage cell fusion, surrounded by CD4+ T-cells and Th17 4.  An imbalance of the Th1/Th2 A
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response towards the Th1 pathway has been incriminated in granuloma formation at the early stage of the 
disease 5. Hence, we could easily hypothesise that dupilumab may directly trigger granulomatosis reactions 
through its anti-IL4 and IL13 effects. Regarding Th17 lymphocytes, IL-4 and 13 have been reported to 
decrease IL-23 production, with reduced Th17 function 6, and thus their inhibition under dupilumab may 
enhance Th17 recruitment and activation.
Nevertheless, such hypothesis would not consider the pivotal role of macrophages in granuloma formation. 
Indeed, a M2 macrophages polarisation state has paradoxically been found as a central mechanism in the 
pathogenesis of sarcoidosis:
- Helming et al. found IL-4 to be a major effector of the macrophage’s fusions and thus of granuloma 
genesis 7
- Locke et al. highlighted recently the key role of IL-13 in macrophage polarisation, in an in vitro model of 
sarcoidosis 8
- A recent study has also brought to light that some M2 macrophages cell surface markers, such as 
CD204, were overexpressed on macrophages from bronchoalveolar fluids of sarcoidosis patients in 
comparison with controls suffering from lung carcinoma 9
Nonetheless, despite these evidences for the role of M2 macrophages polarisation in sarcoidosis 8, redirecting 
macrophage towards a M1 activation could also paradoxically favour granulomatosis formation. Indeed, a 
predominant M1 macrophages activation has also been described in the early stages of granuloma formation in 
in vitro models 10. Thus, exploring the natural history of macrophage polarisation in sarcoidosis and the 
connection between a possible uncontrolled early M1 phase and a secondary ineffective or unadapted M2 
phase may help to decipher the possible involvement of dupilumab in the onset of systemic sarcoid-like 
granulomatosis.
A thorough pharmacovigilance monitoring will henceforth be important for registering future cases, thus 
fostering further investigations of these hypotheses. 
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